With two huge deals in the last two months, Medarex (MEDX) has lifted itself out of the just-scraping-along level of biotech company. In fact, Medarex has almost transformed itself from a developmental stage biotech outfit into the real thing—a commercially viable company. We talk about its drugs, its finances, its prospects.
